LIST OF FIGURES for the Biotechnology Report

Figure 3.1: Biotech Industry Revenues 2002-05
Figure 3.2: Global revenue break-up, 2005
Figure 3.3: Global revenue break-up, 2001-2005
Figure 3.4: Global Industry net loss, 2001-2005
Figure 3.5: R&D expenditure in the industry, 2001-2005
Figure 3.6: Companies in biotech industry, 2001-2005
Figure 3.7: Biotech financing, 1998-2005
Figure 3.8: Major indices (base 100 on January 01, 1998)
Figure 3.9: Global Coverage of GM crops, 1997-2005
Figure 4.1: Financing, the US Biotech companies, 2003-2005
Figure 4.2: Market Capitalization, biotechnology companies, 2000-2005
Figure 6.1: Value chain in Biotechnology Industry
Figure 7.1: Major Region of Biotech Industry, 2001-2005
Figure 7.2: North American GDP, 2001-2005
Figure 7.3: North American Biotech Revenue, 2001-2005
Figure 7.4: North American R&D Expenditure, 2001-2005
Figure 7.5: Biotech Companies in North America, 2001-2005
Figure 7.6: European GDP, 2001-2005
Figure 7.7: European Biotech Revenue, 2001-2005
Figure 7.8: Biotech Companies in Europe, 2001-2005
Figure 7.9: R&D Investment in Europe, 2001-2005
Figure 7.10: Asian GDP, 2001-2005
Figure 7.11: Biotech Revenue in Asia and Asia Pacific, 2001-2005
Figure 7.12: Biotech companies in Asia Pacific, 2001-2005
Figure 7.13: R&D expenditure in Asia, 2001-2005
Figure 8.1: Amgen Inc price movement in 2005 (NASDAQ)
Figure 8.2: Genentech price movement in 2005 (NASDAQ)
Figure 8.3: Genzyme price movement in 2005 (NASDAQ)
Figure 8.4: Serono SA price movement in 2005 (NASDAQ)
Figure 8.5: Biogen Idec price movement in 2005 (NASDAQ)
Figure 8.6: Gilead price movement in 2005 (NASDAQ)
Figure 8.7: Chiron price movement in 2005 (NASDAQ)
Figure 8.8: MedImmune price movement in 2005 (NASDAQ)
Figure 8.9: Invitrogen price movement in 2005 (NASDAQ)
Figure 8.10: Millennium price movement in 2005 (NASDAQ)
Figure 8.11: Monsanto price movement in 2005 (NASDAQ)
Figure 8.12: Syngenta price movement in 2005 (NASDAQ)
Figure 9.1:  Regulatory framework in the US
Figure 9.2: Regulatory framework in India
Figure 9.3: National Biotechnology Development Strategy (Draft), 2005
Figure 10.1: Net value (Top 10 deals) and highest deal
Figure 10.2: Total value of M&A deals (USD mn)
Figure 10.3: Share of Novartis, Pfizer in the top 10 deals, 2005
Figure 11.1: Government initiatives in biotechnology industry, Singapore
Figure 11.2: Government initiatives in biotechnology industry, China
Figure 11.3: Time spent in different R&D activities by a biotechnology company
Figure 11.4: The US biotech financing, 2004
Figure 11.5: Nature of strategic alliances, biotechnology companies
Figure 12.1 Global Biotechnology Market, 2003-06 and 2010
Figure 12.2: Market share of different regions